NU
NUMD.US Nu-Med Plus Inc
- Market cap
- USD 794K
- P/E
- -
- P/B
- 49.86x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NUMD.US undervalued?
Graham numberThe Graham number of Nu-Med Plus Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nu-Med Plus Inc fundamental analysis
No fundamental analysis for Nu-Med Plus Inc yet.
Nu-Med Plus Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nu-Med Plus Inc
Nu-Med Plus, Inc., a medical device company, engages in the design, innovation, development, enhancement, and commercialization of medical devices worldwide. The company develops a nitric oxide generating formulation; a hospital bedside nitric oxide delivery system; a clinical unit for use in medical clinics and rehabilitation centers. It is also involved in the development of a mobile rechargeable device to deliver nitric oxide gas; and a nitric oxide system that can be use…
Full company profileNu-Med Plus Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nu-Med Plus Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | -14.3K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | -14.3K | - | - | - | - | - | - |
| Operating Income | -1.22M | -467K | -1.17M | -1.02M | -1.99M | -839K | -182K | -121K | -63.3K | -49.0K | -71.4K |
| EBITDA | - | 3.63M | -1.15M | -995K | -1.97M | -809K | -119K | -121K | -63.3K | -49.0K | 18.6K |
| Net Income | 9.65M | 3.58M | -1.19M | -1.04M | -2.01M | -830K | -130K | -126K | -68.3K | -56.2K | 7.58K |
| EPS | - | 0.10 | -0.03 | -0.02 | -0.04 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 35.5K | 407K | 423K | 45.8K | 557K | 22.2K | 79.5K | 13.5K | 9.37K | 7.91K | 12.9K |
| Total Liabilities | 4.47M | 338K | 374K | 416K | 89.4K | 155K | 143K | 160K | 224K | 279K | 280K |
| Shareholders' Equity | -4.44M | 68.2K | 48.5K | -370K | 468K | -132K | -63.0K | -147K | -215K | -271K | -267K |
| Cash & Short-term Investments | 12.5K | 351K | 168K | 7.08K | 189K | 11.7K | 73.2K | 6.81K | 2.37K | 661.00 | 5.41K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -180K | -431K | -468K | -567K | -415K | -207K | -38.5K | -66.4K | -4.43K | -48.0K | -10.5K |
| Capital Expenditure | 5.03K | 5.03K | 5.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -431K | -473K | -567K | -415K | -207K | -38.5K | -66.4K | -4.43K | -48.0K | -10.5K |
| Ratios | |||||||||||
| ROE | - | 5,241.6% | -2,449.9% | - | -429.5% | - | - | - | - | - | - |
| ROA | 27,164.9% | 879.5% | -281.0% | -2,264.8% | -360.6% | -3,745.3% | -163.6% | -932.9% | -729.2% | -710.2% | 58.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Nu-Med Plus Inc dividends
Nu-Med Plus Inc has not paid dividends in the last 9 fiscal years.
Who owns Nu-Med Plus Inc
- Insiders 45.04%
- Institutions 0.00%
- Public & others 54.96%
- Shares outstanding 83.5M
- Free float 25.4M
Nu-Med Plus Inc company profile
- Company name
- Nu-Med Plus Inc
- Ticker
- NUMD.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2
- Fiscal year end
- December
- Address
- 640 Belle Terre Road, Port Jefferson, NY, United States, 11777
- Phone
- 631 403 4337
- Website
- nu-medplus.com
About Nu-Med Plus Inc
Nu-Med Plus, Inc., a medical device company, engages in the design, innovation, development, enhancement, and commercialization of medical devices worldwide. The company develops a nitric oxide generating formulation; a hospital bedside nitric oxide delivery system; a clinical unit for use in medical clinics and rehabilitation centers. It is also involved in the development of a mobile rechargeable device to deliver nitric oxide gas; and a nitric oxide system that can be used for research applications, as well as a mobile/portable rechargeable device to deliver inhaled nitric oxide gas. Nu-Med Plus, Inc. was incorporated in 2011 and is based in Port Jefferson, New York.
Nu-Med Plus Inc management
5- Mr. William Charles HaydeExecutive Chairman · born 1965
- Mr. Keith L. MerrellCFO, Principal Accounting Officer, Treasurer, Secretary & Director · born 1946
- Mr. William R. ColvinPresident, CEO & Director · born 1960
- Mr. Fred Antonio-C. Tejada P.Geo.SVP, Chief Geologist & Director · born 1958
- Dr. Craig W. Morrison M.D.Chair of the Medical Advisory Committee · born 1944